Preclinical Incorporation Dosimetry of [18F]FACH-A Novel 18F-Labeled MCT1/MCT4 Lactate Transporter Inhibitor for Imaging Cancer Metabolism with PET.
Overexpression of monocarboxylate transporters (MCTs) has been shown for a variety of human cancers (e.g., colon, brain, breast, and kidney) and inhibition resulted in intracellular lactate accumulation, acidosis, and cell death. Thus, MCTs are promising targets to investigate tumor cancer metabolism with positron emission tomography (PET). Here, the organ doses (ODs) and the effective dose (ED) of the first 18F-labeled MCT1/MCT4 inhibitor were estimated in juvenile pigs. Whole-body dosimetry was performed in three piglets (age: ~6 weeks, weight: ~13-15 kg). The animals were anesthetized and subjected to sequential hybrid Positron Emission Tomography and Computed Tomography (PET/CT) up to 5 h after an intravenous (iv) injection of 156 ± 54 MBq [18F]FACH. All relevant organs were defined by volumes of interest. Exponential curves were fitted to the time-activity data. Time and mass scales were adapted to the human order of magnitude and the ODs calculated using the ICRP 89 adult male phantom with OLINDA 2.1. The ED was calculated using tissue weighting factors as published in Publication 103 of the International Commission of Radiation Protection (ICRP103). The highest organ dose was received by the urinary bladder (62.6 ± 28.9 µSv/MBq), followed by the gall bladder (50.4 ± 37.5 µSv/MBq) and the pancreas (30.5 ± 27.3 µSv/MBq). The highest contribution to the ED was by the urinary bladder (2.5 ± 1.1 µSv/MBq), followed by the red marrow (1.7 ± 0.3 µSv/MBq) and the stomach (1.3 ± 0.4 µSv/MBq). According to this preclinical analysis, the ED to humans is 12.4 µSv/MBq when applying the ICRP103 tissue weighting factors. Taking into account that preclinical dosimetry underestimates the dose to humans by up to 40%, the conversion factor applied for estimation of the ED to humans would rise to 20.6 µSv/MBq. In this case, the ED to humans upon an iv application of ~300 MBq [18F]FACH would be about 6.2 mSv. This risk assessment encourages the translation of [18F]FACH into clinical study phases and the further investigation of its potential as a clinical tool for cancer imaging with PET.
['Sattler|Bernhard|B|0000-0003-3862-2609', 'Kranz|Mathias|M|0000-0002-5641-7396', 'Wenzel|Barbara|B|0000-0001-7390-3575', 'Jain|Nalin T|NT|', 'Moldovan|Rareş-Petru|RP|0000-0003-3119-7945', 'Toussaint|Magali|M|', 'Deuther-Conrad|Winnie|W|0000-0003-3168-3062', 'Ludwig|Friedrich-Alexander|FA|', 'Teodoro|Rodrigo|R|0000-0002-1425-0567', 'Sattler|Tatjana|T|', 'Sadeghzadeh|Masoud|M|0000-0002-6844-6637', 'Sabri|Osama|O|', 'Brust|Peter|P|0000-0001-5555-7058']
D000818:Animals D001853:Bone Marrow D005462:Fluorine Radioisotopes D027501:Monocarboxylic Acid Transporters D009369:Neoplasms D000072078:Positron Emission Tomography Computed Tomography D011874:Radiometry D019275:Radiopharmaceuticals D013270:Stomach D013552:Swine D027981:Symporters D014018:Tissue Distribution D014057:Tomography, X-Ray Computed D001743:Urinary Bladder
MCT1/MCT4 lactate transporter inhibitor [18F]FACH OLINDA image-based internal dosimetry preclinical radiopharmaceutical dosimetry radiation safety